CannabisNewsBreaks

WednesdayOct 04, 2017 9:36 am

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Enters Collaboration and Licensing Agreement with Canntab Therapeutics

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) yesterday announced its entry into a collaboration and licensing agreement with Canntab Therapeutics Limited, developer of a patent-pending oral sustained release formulation for cannabinoids. Per the terms of the agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of this sustained release product, with Emblem receiving the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing and commercializing the innovative product under the Emblem brand. Manufacture of the sustained release product is expected to be completed by Emblem or Canntab following…

Continue Reading

TuesdayOct 03, 2017 1:24 pm

CannabisNewsBreaks – DOJA Cannabis Company (CSE: DOJA) Expands Production Capacity with Building Acquisition in Kelowna

DOJA Cannabis Company (CSE: DOJA) this morning said the courts have approved its offer to acquire a 22,580 sq.ft. building in Kelowna, British Columbia, out of bankruptcy protection. The closing of the acquisition is anticipated to take place on October 27. The company is also building a new facility which, upon completion, will raise DOJA’s corporate cannabis production capacity to more than 5,000 kg per year. “The acquisition is a game changer for DOJA, it allows us to expand our production capacity by almost 8 times, diversify our strain production, integrate a world class extraction lab and leverage the economies…

Continue Reading

TuesdayOct 03, 2017 1:23 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More

Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action. Lexaria intends to out-license this patented and proprietary technology, and the company has already applied this delivery technology to its line of products, which includes ViPova, Lexaria Energy and TurboCBD. An article further discussing this reads: “Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of…

Continue Reading

TuesdayOct 03, 2017 9:28 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Filing of Provisional Patent for Cannabinoid-Based Pain Treatment

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, marking an important step toward protection of the company’s intellectual and commercial property. “There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” Dr. Sazzad Hossain, chief scientific officer of InMed and a co-inventor on the newly-filed…

Continue Reading

FridaySep 29, 2017 3:01 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Achieves $43M in Working Capital, Eyes Substantial Production Capacity Increase for 2018

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), a manufacturer and distributor of medical cannabis in Canada, announced on August 29 (http://cnw.fm/X6GSl) the achievement of working capital in the amount of $43 million from multiple financings, including strategic partnerships and private placements, during the six months ended June 30, 2017. During that period, ABcann recorded revenues of C$264,319, compared with $21,465 during the same period of 2016. For the six-month period ended June 30, the company’s revenues were $436,802, as compared with $21,840 for comparable period of the previous year. An article further discussing this reads: “ABcann’s first quarter as a…

Continue Reading

ThursdaySep 28, 2017 12:31 pm

CannabisNewsBreaks – Alternate Health (CSE: AHG) (OTCQB: AHGIF) Announces Launch of Cannabis Blockchain Transaction Ledger

Alternate Health Corp. (CSE: AHG) (OTCQB: AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance and appropriate usage of cannabinoids in modern medical practices, recently announced the rebranding of its CanaCard software to the CanaPass Patient Management System with the goal of integrating mobile technology and providing a blockchain ledger for the purposes of transparency and accountability. “The evolution of CanaPass is a natural step forward in Alternate Health’s software development as we continuously update and adapt the system to changes in technology," Dr. Michael Murphy, CEO of…

Continue Reading

TuesdaySep 26, 2017 3:34 pm

CannabisNewsBreaks – Pivot Pharmaceuticals (PVOTF) and Solmic Research GmbH Sign License and Collaboration Agreement for Improved Oral Formulations of Cannabinoids

Pivot Pharmaceuticals (OTCQB: PVOTF) and its medical cannabis product division, Pivot Green Stream Health Solutions, recently announced the signing of a definitive agreement with Solmic Research GmbH (Germany) which gives Pivot Pharmaceuticals worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts. Solmic’s proprietary technology provides higher bioavailability and stability compared to alternative oil-based formulations. Solmic’s technology allows active ingredients to become water soluble without changing their composition and nature. To view the full article, visit http://cnw.fm/Ew0e4 About Pivot Pharmaceuticals Inc. Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company…

Continue Reading

MondaySep 25, 2017 9:33 am

CannabisNewsBreaks – The Green Organic Dutchman (“TGOD”) Introduces New CFO and VP of Horticulture

The Green Organic Dutchman Holdings Ltd. (“TGOD”) recently announced the hiring of Amy Stephenson as its new chief financial officer and David Peron as its new vice president of horticulture. Stephenson has over 20 years of executive experience in both the private and public sectors which includes working with market leaders in the Canadian cannabis industry. Peron is an agrologist and holds a master of science degree in plant sciences from McGill University. He is also chief science officer for Destiny Biotechnology, which provides living soil systems for organic cannabis production. “This is another step forward for The Green Organic…

Continue Reading

MondaySep 25, 2017 9:08 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on Advancements of Proprietary Biosynthesis Technology

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be further functionalized to produce any of the 90+ cannabinoids that occur naturally in the cannabis plant. “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed,” Eric A. Adams, president and CEO of InMed, stated in…

Continue Reading

ThursdaySep 21, 2017 9:21 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index. Per the update, the CSE25 Index is a subgroup of the CSE Composite Index, which was launched in 2015 and currently includes nearly half of the exchange’s listed companies and over 75 percent of the trading activity on the Canadian Securities Exchange. The CSE25 Index includes the top 25 securities contained within the CSE Composite Index based on market capitalization. According to the…

Continue Reading